Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APYX NASDAQ:LUCD NASDAQ:LUNG NASDAQ:PDEX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPYXApyx Medical$4.11-2.4%$3.98$1.59▼$5.08$176.29M1.39156,350 shs194,791 shsLUCDLucid Diagnostics$1.07+8.4%$1.08$0.90▼$1.63$199.55M1.08932,173 shs6.01 million shsLUNGPulmonx$1.28+2.0%$1.40$1.13▼$3.88$52.80M0.28333,107 shs619,926 shsPDEXPro-Dex$64.37+6.5%$58.57$23.47▼$68.99$193.03M-0.0261,459 shs43,378 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPYXApyx Medical+1.45%-8.68%+8.79%+19.26%+139.20%LUCDLucid Diagnostics-3.66%-2.70%+2.89%-23.23%-20.11%LUNGPulmonx0.00%-12.59%-4.58%-10.07%-53.87%PDEXPro-Dex-2.98%-2.45%+2.20%+23.39%+41.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPYXApyx Medical$4.11-2.4%$3.98$1.59▼$5.08$176.29M1.39156,350 shs194,791 shsLUCDLucid Diagnostics$1.07+8.4%$1.08$0.90▼$1.63$199.55M1.08932,173 shs6.01 million shsLUNGPulmonx$1.28+2.0%$1.40$1.13▼$3.88$52.80M0.28333,107 shs619,926 shsPDEXPro-Dex$64.37+6.5%$58.57$23.47▼$68.99$193.03M-0.0261,459 shs43,378 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPYXApyx Medical+1.45%-8.68%+8.79%+19.26%+139.20%LUCDLucid Diagnostics-3.66%-2.70%+2.89%-23.23%-20.11%LUNGPulmonx0.00%-12.59%-4.58%-10.07%-53.87%PDEXPro-Dex-2.98%-2.45%+2.20%+23.39%+41.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPYXApyx Medical 2.67Moderate Buy$6.5058.15% UpsideLUCDLucid Diagnostics 2.60Moderate Buy$4.19293.19% UpsideLUNGPulmonx 2.43Hold$5.58337.91% UpsidePDEXPro-Dex 2.33Hold$70.008.75% UpsideCurrent Analyst Ratings BreakdownLatest LUNG, PDEX, APYX, and LUCD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026LUCDLucid Diagnostics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $9.255/19/2026PDEXPro-Dex Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/15/2026LUCDLucid Diagnostics Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.00 ➝ $2.005/15/2026LUCDLucid Diagnostics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$2.505/12/2026PDEXPro-Dex Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $70.005/6/2026LUCDLucid Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/1/2026PDEXPro-Dex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)4/30/2026LUNGPulmonx D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.004/9/2026LUCDLucid Diagnostics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.25 ➝ $9.003/30/2026LUCDLucid Diagnostics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$2.503/27/2026APYXApyx Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPYXApyx Medical$52.84M3.26N/AN/A$0.39 per share10.54LUCDLucid Diagnostics$5.13M42.12N/AN/A($0.31) per share-3.44LUNGPulmonx$90.50M0.60N/AN/A$1.31 per share0.97PDEXPro-Dex$66.59M3.08$3.24 per share19.87$11.23 per share5.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPYXApyx Medical-$11.21M-$0.22N/AN/AN/A-16.40%-88.47%-14.94%8/6/2026 (Estimated)LUCDLucid Diagnostics-$58.01M-$0.47N/AN/AN/A-876.72%N/A-116.26%8/12/2026 (Estimated)LUNGPulmonx-$54M-$1.30N/AN/AN/A-60.09%-92.94%-39.80%7/29/2026 (Estimated)PDEXPro-Dex$8.98M$3.6217.7823.15N/A16.08%22.78%14.30%7/8/2026 (Estimated)Latest LUNG, PDEX, APYX, and LUCD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026LUCDLucid Diagnostics-$0.05-$0.07-$0.02-$0.17$1.38 million$1.26 million5/7/2026Q1 2026APYXApyx Medical-$0.11-$0.05+$0.06-$0.05$10.53 million$12.49 million4/30/2026Q3 2026PDEXPro-Dex$0.62$1.20+$0.58$1.20$17.90 million$19.95 million4/29/2026Q1 2026LUNGPulmonx-$0.33-$0.33N/A-$0.33$20.43 million$20.59 million3/25/2026Q4 2025LUCDLucid Diagnostics-$0.07-$0.10-$0.03-$0.12$1.39 million$1.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPYXApyx MedicalN/AN/AN/AN/AN/ALUCDLucid DiagnosticsN/AN/AN/AN/AN/ALUNGPulmonxN/AN/AN/AN/AN/APDEXPro-DexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPYXApyx Medical2.685.804.79LUCDLucid DiagnosticsN/A1.071.05LUNGPulmonx0.814.914.04PDEXPro-Dex0.323.672.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPYXApyx Medical55.33%LUCDLucid Diagnostics74.01%LUNGPulmonx91.04%PDEXPro-Dex15.28%Insider OwnershipCompanyInsider OwnershipAPYXApyx Medical15.20%LUCDLucid Diagnostics6.90%LUNGPulmonx6.80%PDEXPro-Dex45.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPYXApyx Medical27041.87 million35.51 millionOptionableLUCDLucid Diagnostics70203.07 million189.06 millionNo DataLUNGPulmonx25042.24 million39.37 millionOptionablePDEXPro-Dex1403.19 million1.73 millionNot OptionableLUNG, PDEX, APYX, and LUCD HeadlinesRecent News About These CompaniesPro-Dex Inc.June 18 at 4:33 AM | barrons.comPro-Dex Issues Updated Investor Presentation Under Regulation FDJune 17 at 7:10 PM | tipranks.comPro-Dex (NASDAQ:PDEX) Upgraded by Wall Street Zen to "Buy" RatingJune 13, 2026 | americanbankingnews.comPro-Dex (NASDAQ:PDEX) Share Price Crosses Above Two Hundred Day Moving Average - Here's WhyJune 11, 2026 | americanbankingnews.comPro-Dex’s (PDEX) Acquisition Costs Now, Gains in FutureJune 3, 2026 | insidermonkey.comInsider Selling: Pro-Dex (NASDAQ:PDEX) CEO Sells 4,128 Shares of StockMay 27, 2026 | insidertrades.comPro-Dex Insider Trading Activity | NASDAQ:PDEX | BenzingaMay 22, 2026 | benzinga.comPro-Dex, Inc. Announces Fiscal 2026 Third Quarter and Nine Month ResultsApril 30, 2026 | accessnewswire.comAIs Now The Time To Put Pro-Dex (NASDAQ:PDEX) On Your Watchlist?April 16, 2026 | finance.yahoo.comPro-Dex Completes Acquisition of Advanced Precision MachiningFebruary 12, 2026 | tipranks.comPro-Dex, Inc. Announces Acquisition of Advanced Precision MachiningFebruary 12, 2026 | accessnewswire.comAPro-Dex, Inc. Announces Fiscal 2026 Second Quarter and Six-Month ResultsJanuary 29, 2026 | accessnewswire.comAWith 37% ownership, Pro-Dex, Inc. (NASDAQ:PDEX) has piqued the interest of hedge funds investorsJanuary 25, 2026 | uk.finance.yahoo.comPro-Dex: A Niche Surgical Tools Microcap Trading At A DiscountJanuary 17, 2026 | seekingalpha.comPro-Dex Valuation Is Attractive Despite Customer RiskJanuary 8, 2026 | seekingalpha.comPro-Dex stock surges after securing three-year contract extensionDecember 22, 2025 | za.investing.comPro-Dex, Inc. Announces Contract Extension With Largest CustomerDecember 19, 2025 | accessnewswire.comAInvestors Could Be Concerned With Pro-Dex's (NASDAQ:PDEX) Returns On CapitalDecember 13, 2025 | finance.yahoo.comLong Cast Advisers’ Updates on Pro-Dex (PDEX)December 1, 2025 | msn.comPro-Dex's (NASDAQ:PDEX) investors will be pleased with their notable 81% return over the last three yearsNovember 22, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Silver Lining of Last Week's Hims & Hers Earnings MissBy Jessica Mitacek | May 21, 2026Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 BillionBy Jeffrey Neal Johnson | June 11, 2026Short Sellers Are Piling Into Wingstop, But Analysts See Big UpsideBy Jennifer Ryan Woods | June 10, 2026LUNG, PDEX, APYX, and LUCD Company DescriptionsApyx Medical NASDAQ:APYX$4.11 -0.10 (-2.38%) Closing price 04:00 PM EasternExtended Trading$4.05 -0.06 (-1.46%) As of 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.Lucid Diagnostics NASDAQ:LUCD$1.06 +0.08 (+8.37%) Closing price 03:59 PM EasternExtended Trading$1.08 +0.02 (+1.88%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.Pulmonx NASDAQ:LUNG$1.27 +0.03 (+2.00%) Closing price 03:59 PM EasternExtended Trading$1.27 0.00 (0.00%) As of 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Pro-Dex NASDAQ:PDEX$64.37 +3.91 (+6.47%) Closing price 04:00 PM EasternExtended Trading$64.30 -0.07 (-0.11%) As of 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Jabil Just Gave Investors a Stronger Reason to Buy the Dip USA Rare Earth Just Moved Closer to Commercial Reality After an Initial Panic, Wall Street's Leaning Into Apple's New Siri AI CoreWeave Insider Sales Look Big, But Should Investors Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
